411 related articles for article (PubMed ID: 20160534)
41. Pulmonary hypertension in connective tissue diseases: What every CTD specialist should know - but is afraid to ask!
Sanges S; Sobanski V; Lamblin N; Hachulla E; Savale L; Montani D; Launay D
Rev Med Interne; 2024 Jan; 45(1):26-40. PubMed ID: 37925256
[TBL] [Abstract][Full Text] [Related]
42. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
[TBL] [Abstract][Full Text] [Related]
43. Pulmonary hypertension associated with connective tissue disease.
Fagan KA; Badesch DB
Prog Cardiovasc Dis; 2002; 45(3):225-34. PubMed ID: 12525998
[TBL] [Abstract][Full Text] [Related]
44. Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Sobanski V; Giovannelli J; Lynch BM; Schreiber BE; Nihtyanova SI; Harvey J; Handler CE; Denton CP; Coghlan JG
Arthritis Rheumatol; 2016 Feb; 68(2):484-93. PubMed ID: 26415038
[TBL] [Abstract][Full Text] [Related]
45. The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.
Zhao J; Wang Q; Deng X; Qian J; Tian Z; Liu Y; Li M; Zeng X
Pharmacol Ther; 2022 Nov; 239():108192. PubMed ID: 35461923
[TBL] [Abstract][Full Text] [Related]
46. Endothelin receptor antagonists in pulmonary arterial hypertension.
Dupuis J; Hoeper MM
Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
[TBL] [Abstract][Full Text] [Related]
47. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
[TBL] [Abstract][Full Text] [Related]
48. [The clinical analysis of pulmonary arterial hypertension in connective tissue disease].
Ji YQ; Zhang ZL; Lu WX
Zhonghua Nei Ke Za Zhi; 2006 Jun; 45(6):467-71. PubMed ID: 16831323
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension.
Kularatne M; Boucly A; Savale L; Solinas S; Cheron C; Roche A; Jevnikar M; Jaïs X; Montani D; Humbert M; Sitbon O
Expert Opin Pharmacother; 2023; 24(18):2101-2115. PubMed ID: 37869785
[TBL] [Abstract][Full Text] [Related]
50. New paradigm for pulmonary arterial hypertension treatment.
Tamura Y; Channick RN
Curr Opin Pulm Med; 2016 Sep; 22(5):429-33. PubMed ID: 27434819
[TBL] [Abstract][Full Text] [Related]
51. Effect of ambrisentan on digital ulcers in systemic sclerosis: a case report.
Tomaselli V; D'Ambrosio D; Massarelli L; Roccatello D
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-230-1. PubMed ID: 24774305
[No Abstract] [Full Text] [Related]
52. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
Mittoo S; Jacob T; Craig A; Bshouty Z
Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
[TBL] [Abstract][Full Text] [Related]
53. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Gaine S; Chin K; Coghlan G; Channick R; Di Scala L; Galiè N; Ghofrani HA; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Hoeper MM
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28818881
[TBL] [Abstract][Full Text] [Related]
54. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.
Condliffe R; Kiely DG; Peacock AJ; Corris PA; Gibbs JS; Vrapi F; Das C; Elliot CA; Johnson M; DeSoyza J; Torpy C; Goldsmith K; Hodgkins D; Hughes RJ; Pepke-Zaba J; Coghlan JG
Am J Respir Crit Care Med; 2009 Jan; 179(2):151-7. PubMed ID: 18931333
[TBL] [Abstract][Full Text] [Related]
55. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
[TBL] [Abstract][Full Text] [Related]
56. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.
Khanna D; Gladue H; Channick R; Chung L; Distler O; Furst DE; Hachulla E; Humbert M; Langleben D; Mathai SC; Saggar R; Visovatti S; Altorok N; Townsend W; FitzGerald J; McLaughlin VV;
Arthritis Rheum; 2013 Dec; 65(12):3194-201. PubMed ID: 24022584
[TBL] [Abstract][Full Text] [Related]
57. [Clinical analysis of 79 pulmonary arterial hypertension cases from 1892 connective tissue disease patients].
Lei YX; Zhang X; Cui Y; Dong GF; Luo RQ
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(41):2934-7. PubMed ID: 20137654
[TBL] [Abstract][Full Text] [Related]
58. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Montani D; Humbert M
Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
[No Abstract] [Full Text] [Related]
59. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Humbert M
Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
[No Abstract] [Full Text] [Related]
60. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG
Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
